Vanda Pharmaceuticals (VNDA) Change in Accured Expenses (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Change in Accured Expenses data on file, last reported at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 73.74% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $11.7 million (up 88.77% YoY), and the FY2025 full-year result was $15.8 million, up 826.23% from the prior year.
• Change in Accured Expenses declined to $1.5 million in Q1 2026, from $9.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $13.4 million in Q1 2022 to a low of -$10.8 million in Q1 2023.
• A 5-year average of $1.2 million and a median of $1.2 million in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses soared 4878.57% in 2022 and tumbled 2079.74% in 2025, its largest moves.
• Tracing VNDA's Change in Accured Expenses over 5 years: stood at -$3.3 million in 2022, then soared by 201.65% to $3.3 million in 2023, then slumped by 163.85% to -$2.1 million in 2024, then surged by 526.75% to $9.1 million in 2025, then tumbled by 83.7% to $1.5 million in 2026.
• Business Quant data shows VNDA's Change in Accured Expenses at $1.5 million in Q1 2026, $9.1 million in Q4 2025, and -$10.2 million in Q3 2025.